FDA approves first treatment for all HCV genotypes in CHILDREN (USA)

FDA approves MAVYRET™, the first treatment for all genotypes of hepatitis C approved by this US agency for pediatric use. On behalf of Canada's children, we hope Canada will soon follow (Canada's version of AbbVie's hepatitis C drug is spelled Maviret™)! For Immediate Release, April 30, 2019 https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-all-genotypes-hepatitis-c-pediatric-patients

BC PharmaCare lists Maviret™ treatment for HCV

Congratulations, hepatitis C patients in BC, BC PharmaCare, and AbbVie Pharmaceuticals! One more treatment option is now available to BC HCV patients of all genotypes, New patients without cirrhosis need only 8 weeks treatment. Maviret™ is also safe and effective for the many HCV+ people with chronic kidney disease (CKD). More information: https://www.newswire.ca/news-releases/british-columbia-pharmacare-lists-abbvie-s-hepatitis-c-treatment-mavi...

The Week in Review: Jan. 25, 2019 – Feb. 22, 2019

Friday, Feb. 22, 2019 News Recap: Time to Change Protocols for Post-SVR Monitoring for Liver Cancer? In Memoriam: Anita York (May 27, 1953 - Feb. 7, 2019) Funding via “Womens Wellness & Leadership Project” for women in BC living with HCV (&/or HIV) MAVIRET™ 8 week, pan-genotypic HCV treatment, good for CKD & cirrhosis, covered in Ontario No Time to Relax about Liver Cancer after HCV Treatment: Time to Change Monitoring

MAVIRET™ 8 week, pan-genotypic HCV treatment, good for CKD & cirrhosis, covered in Ontario

Finally, Maviret, AbbVie's hepatitis C drug, has made it through Canada's approval process and has been listed for coverage by Ontario's PharmaCare. We hope BC PharmaCare will also list it soon. "MAVIRET™ is the first and only 8-week, pan-genotypic treatment for chronic hepatitis C patients without cirrhosis and who are new to treatment (from: Decisions Resources Group. Hepatitis C virus: disease landscape & forecast 2016 and 2017)... MA...

The Week in Review: Dec 14 – Dec 21, 2018

Friday, Dec 21, 2018 News Recap: ***COMMUNITY DINNER January 10th at OUR PLACE in HONOUR of PHIL WILKIN*** Philip Wilkin, who passed away unexpectedly on Nov. 24th, 2018, was a man with the true spirit of giving. Phil sat on various committees designed to improve health and welfare of prisoners within the Canadian Prison System, and actively advocated for education, treatment and prevention. To help celebrate his achievements, HepCBC has set up a Go...

NZ: Pharmac to fund new Hep C treatment

Up to 50,000 people are expected to benefit from the funding of a new treatment for those with hepatitis C. That's the number of New Zealanders estimated to have the blood-borne disease that's transmitted mainly through intravenous needles or badly sterilised medical equipment. Hepatitis C targets the liver and can be fatal. Drug-buyer Pharmac today announced that from February it'll fund the drug Maviret for those with hepatitis C regardless of the ty

AbbVie receives a positive recommendation from the CADTH Canadian Drug Expert Committee for MAVIRET™ – an oral therapy for the treatment of patients with hepatitis C

MAVIRET is the first and only 8-week, pan-genotypic treatment for chronic hepatitis C patients without cirrhosis and who are new to treatment*1 MAVIRET previously received a Notice of Compliance from Health Canada on August 16, 2017 MAVIRET is the only pan-genotypic treatment approved for use in patients across all stages of chronic kidney disease MONTREAL, Feb. 6, 2018 /CNW/ - AbbVie (NYSE: ABBV), a global, research and development-based ...

CDEC Recommends MAVIRET™ and VOSEVI™ for Reimbursement for Chronic HCV

On January 25, 2018 the federal CADTH Canadian Drug Expert Committee (CDEC) released its extensive reviews of two new "pan-genotypic" hepatitis C treatments: Maviret™ (AbbVie) and Vosevi™ (Gilead). In both cases, the drugs were recommended for reimbursement by provincial PharmaCares for "adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis." And, for both, reimburseme...

Shorter duration of glecaprevir-pibrentasvir effective against hepatitis C virus: The ENDURANCE trials

Treatment options for patients with chronic HCV continue to evolve, and effective agents with shorter treatment duration are needed to decrease morbidity. The coformulation of the nonstructural (NS) 3/4A protease inhibitor glecaprevir and NS5A inhibitor pibrentasvir was approved for the treatment of patients with HCV genotypes 1-6 without cirrhosis has demonstrated pangenotypic efficacy, a favorable safety profile, high barrier to resistance, and synergist

The Week in Review: October 6 – October 13, 2017

Friday, October 13, 2017 News Recap: Research & Discoveries After an intense hunt, researchers at the Norwegian University of Science and Technology (NTNU) can now describe an important part of the disease's guerrilla tactics: how hepatitis C converts innocent cells into outright virus factories.  How hepatitis C hides in the body. Apparently, liver cancer can be caught at an early stage through a newly developed blood test, improving the odd...